Flare of Antiphospholipid Syndrome in the Course of COVID-19

This article was originally published here

TH Open. 2020 Sep 11;4(3):e207-e210. doi: 10.1055/s-0040-1716735. eCollection 2020 Jul.


We report the case of a 48-year-old man followed since 2013 for primary antiphospholipid syndrome (APLS) revealed by venous thromboembolism in the presence of antiphospholipid antibodies (APL-Abs, anticardiolipin and anti-β-2-glycoprotein-1), who decompensated in the course of coronavirus disease (COVID-19). Despite efficient anticoagulation, he suffered bilateral adrenal glands hemorrhage and limb arterial ischemia. The tropism of severe acute respiratory syndrome coronavirus-2 for endothelium can lead to microangiopathy and increased risk for thrombosis. If APL-Abs positivity can be an epiphenomenon under inflammatory and prothrombotic conditions, COVID-19 was herein responsible for disseminated thrombosis and a threat of catastrophic APLS, despite efficient anticoagulation.

PMID:32935073 | PMC:PMC7486139 | DOI:10.1055/s-0040-1716735